Due to the unprecedented nature of the COVID-19 pandemic, anyone reporting an Adverse Event and/or a Product Complaint via phone, should you receive a network busy signal (ie: if all lines busy/engaged) please continue to try your call throughout the day. Alternatively, you may email your Adverse Event to drugsafety@propharmagroup.com OR Product Complaint to productcomplaint@propharmagroup.com, OR medical information request to MedInfo@propharmagroup.com.

Day

April 15, 2014
15
Apr

Esmolol Hydrochloride Premixed Injection Tentatively Approved

April 15, 2014,
For More Information, Contact: Michele Scrofani, Vice President HQ Specialty Pharma, LLC 201.857.8290     Paramus, NJ, April 15, 2014 – HQ Specialty Pharma and its collaborating partner, WelGrace Research Group, have received tentative approval on its 505(b)(2) application for Esmolol Hydrochloride Premixed Injection, which references Brevibloc® Injection. The product will be available in two...
Read More
© 2020 WG Critical Care, LLC | A PharmaSphere Company | 120 Rte 17 N, Paramus, NJ 07652